Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Yervoy receives approval for unresectable malignant melanoma in Japan

July 3, 2015

Scientists disclose phase I results for PepCan

July 2, 2015

Safety board recommends phase III rindopepimut study continue

July 2, 2015

Clinical activity seen with AM-0010 in first-in-human trial

July 1, 2015

FDA accepts IND for phase I trial of JCAR-017 for relapsed/refractory B-cell NHL

June 30, 2015

rF-GM-CSF and rF-TRICOM are safe is patients with bladder carcinoma

June 30, 2015

Patrys awards Chinese license for cancer therapy PAT-SC1

June 30, 2015

Immunovaccine and Incyte collaborate to investigate combination of DPX-Survivac and epacadostat

June 30, 2015

Novogen advances anisina towards clinic

June 29, 2015

Calithera selects oral arginase inhibitor CB-1158 as immuno-oncology clinical candidate

June 26, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...